GPP
Great Point Partners Portfolio holdings
AUM
$154M
This Quarter Return
+10.61%
1 Year Return
-2.36%
3 Year Return
+169.3%
5 Year Return
+292.82%
10 Year Return
+3,519.88%
AUM
$484M
AUM Growth
+$484M
(+16%)
Cap. Flow
+$82.3M
Cap. Flow
% of AUM
17.02%
Top 10 Holdings %
Top 10 Hldgs %
51.89%
Holding
57
New
15
Increased
16
Reduced
7
Closed
15
Top Buys
| 1 |
RAPT Therapeutics
RAPT
|
$22.2M |
| 2 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
$17.7M |
| 3 |
Ultragenyx Pharmaceutical
RARE
|
$15.9M |
| 4 |
OPTN
OptiNose
OPTN
|
$14.6M |
| 5 |
Viking Therapeutics
VKTX
|
$12.2M |
Top Sells
| 1 |
Relmada Therapeutics
RLMD
|
$18.9M |
| 2 |
Galapagos
GLPG
|
$13.1M |
| 3 |
Alkermes
ALKS
|
$12.1M |
| 4 |
BridgeBio Pharma
BBIO
|
$10.4M |
| 5 |
Travere Therapeutics
TVTX
|
$10.3M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Vaxcyte
PCVX
$4B
| $38.4M | 7.52% | 800,000 +200,000 | +33% | +$9.59M |
|
2
Xenon Pharmaceuticals
XENE
$2.98B
| $33.5M | 6.57% | 850,000 | – | – |
|
|
3
RAPT Therapeutics
RAPT
$188M
| $28.4M | 5.58% | 1,436,569 +1,121,569 | +356% | +$22.2M |
|
|
ALPN
4
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| $26.7M | 5.24% | 3,637,718 +189,197 | +5% | +$1.39M |
|
5
Pliant Therapeutics
PLRX
$101M
| $25.6M | 5.01% | 1,322,870 +281,133 | +27% | +$5.43M |
|
6
Jazz Pharmaceuticals
JAZZ
$7.75B
| $25.5M | 5% | 160,000 -55,000 | -26% | -$8.76M |
|
|
SGEN
7
DELISTED
Seagen Inc. Common Stock
SGEN
| $20.6M | 4.04% | 160,500 +84,000 | +110% | +$10.8M |
|
|
PNT
8
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
| $18.5M | 3.63% | 2,541,779 -1,019,205 | -29% | -$7.43M |
|
|
ISEE
9
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $17.7M | 3.46% | +825,000 | New | +$17.7M |
|
10
Aclaris Therapeutics
ACRS
$209M
| $16.1M | 3.15% | 1,019,282 | – | – |
|
11
Heron Therapeutics
HRTX
$207M
| $15.9M | 3.12% | 6,360,161 +715,000 | +13% | +$1.79M |
|
|
12
Ultragenyx Pharmaceutical
RARE
$2.89B
| $15.9M | 3.11% | +342,300 | New | +$15.9M |
|
|
OPTN
13
DELISTED
OptiNose
OPTN
| $14.6M | 2.86% | +7,894,736 | New | +$14.6M |
|
14
Ventyx Biosciences
VTYX
$171M
| $13.1M | 2.58% | 400,695 +130,728 | +48% | +$4.29M |
|
|
CINC
15
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
| $12.5M | 2.46% | 1,019,153 +717,829 | +238% | +$8.82M |
|
|
16
Viking Therapeutics
VKTX
$3.04B
| $12.2M | 2.39% | +1,295,034 | New | +$12.2M |
|
17
Day One Biopharmaceuticals
DAWN
$769M
| $11.7M | 2.3% | 544,451 +473,830 | +671% | +$10.2M |
|
18
PTC Therapeutics
PTCT
$3.92B
| $11.5M | 2.26% | +302,135 | New | +$11.5M |
|
|
JBIO
19
Jade Biosciences, Inc. Common Stock
JBIO
$258M
| $11.1M | 2.17% | +378,522 | New | +$11.1M |
|
|
20
Travere Therapeutics
TVTX
$1.56B
| $9.99M | 1.96% | 475,000 -491,108 | -51% | -$10.3M |
|
|
CBAY
21
DELISTED
Cymabay Therapeutics
CBAY
| $9.72M | 1.9% | 1,550,000 +750,561 | +94% | +$4.71M |
|
22
Sarepta Therapeutics
SRPT
$1.78B
| $9.46M | 1.85% | +73,000 | New | +$9.46M |
|
23
KalVista Pharmaceuticals
KALV
$678M
| $7.14M | 1.4% | 1,055,801 -495,918 | -32% | -$3.35M |
|
24
Amylyx Pharmaceuticals
AMLX
$836M
| $7.02M | 1.38% | +190,000 | New | +$7.02M |
|
25
MoonLake Immunotherapeutics
MLTX
$3.54B
| $6.75M | 1.32% | 642,566 +150,566 | +31% | +$1.58M |
|